CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
Lung cancer-specific T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03356808
NCT03356808Phase 1RecruitingMonitor
Slow Enrollment
CompareCT.gov

Multicenter Trial of Cancer Antigen-specific T Cells in the Treatment of Lung Cancer

Shenzhen Geno-Immune Medical Institute·interventional·Posted Nov 29, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating Lung cancer-specific T cells for Lung Cancer. Currently recruiting, targeting 20 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedNov 29, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years

Arms & Interventions

Lung cancer-specific T cellsexperimental

Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.

Biological: Lung cancer-specific T cells

Interventions

Lung cancer-specific T cellsbiological

1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV